# US 2018/0022702 A1 · Piperidine derivatives as hdac1/2 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022702 A1
- Document ID: US20180022702A1
- Status: Published application
- Kind: A1
- Application number: 15/719,748
- Filed: 2017-09-29
- Published: 2018-01-25
- Earliest claimed: 2014-12-12
- Assignees: Regenacy Pharmaceuticals, LLC
- Applicants: Regenacy Pharmaceuticals, LLC
- Inventors: John H. van Duzer; Ralph Mazitschek
- Web page: https://patentgrep.com/patent/US20180022702A1

## CPC

- C07D 211/58: attached in position 4
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof,
wherein,
X1 is CR7 or N;
X2 is CH or N; wherein at least one of X1 or X2 is N;
Y is selected from the group consisting of:
Z is selected from the group consisting of H, C1-C6-alkyl, C6-aryl, C(O)NR4R5, C(O)OR6, C(O)C1-C6-alkyl, C(O)C0-C6-alkyl-C6-aryl, C(O)—C3-C6-cycloalkyl, C(O)—C2-C6-heterocyclyl, and C(O)C0-6-alkyl-heteroaryl, wherein the aryl, heteroaryl, cycloalkyl, and heterocyclyl groups are optionally substituted by 1 or 2 of C1-C6-alkyl, halo, C1-C6-haloalkyl, hydroxy, or C1-C6-alkoxy;
Ra and Rb are H, or Ra and Rb together form a fused C6-aryl;
R1 is selected from the group consisting of H and C1-C6-alkyl;
R2 is selected from the group consisting of H, C1-C6-alkyl, and C6-aryl;
R3 is selected from the group consisting of H, C1-C6-alkyl, and C6-aryl;
or R2 and R3 together form a C2-C6-heterocyclyl;
R4 is selected from the group consisting of H, C1-C6-alkyl, C1-C6-alkyl-OH, and C1-C6—NH2;
R5 is C1-C6-alkyl;
or R4 and R5 together form a C2-C6-heterocyclyl, wherein heterocyclyl is optionally substituted by 1 or 2 of C1-C6-alkyl, halo, C1-C6-haloalkyl, hydroxy, or C1-C6-alkoxy;
R6 is selected from the group consisting of C1-C6-alkyl and C0-6-alkyl-C6-aryl, wherein aryl is optionally substituted by 1 or 2 of C1-C6-alkyl, halo, or hydroxy; and
R7 is selected from the group consisting of H, C1-C6-alkyl, and C3-C6-cycloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, having the structure of Formula II:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein X1 and X2 are each N.

### Claim 4 (depends on 1)

The compound of claim 1, wherein Y is:

### Claim 5 (depends on 1)

The compound of claim 1, wherein Z is selected from the group consisting of C(O)NR4R5, C(O)OR6, C(O)—C3-C6-cycloalkyl, C(O)—C2-C6-heterocyclyl, and C(O)C0-6-alkyl-heteroaryl, wherein heteroaryl, cycloalkyl, or heterocyclyl are optionally substituted by 1 or 2 of C1-C6-alkyl, halo, or hydroxy; and
R6 is C6-aryl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein Z is selected from the group consisting of H, C1-C6-alkyl, and C6-aryl.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R1 is H.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R2 is H.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R3 is H, methyl, ethyl, isopropyl, or phenyl.

### Claim 10 (depends on 1)

The compound of claim 1, having the structure of Formula III:
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 10)

The compound of claim 10, wherein X1 and X2 are each N.

### Claim 12 (depends on 10)

The compound of claim 10, wherein R2 is H.

### Claim 13 (depends on 10)

The compound of claim 10, wherein R3 is H, methyl, or isopropyl.

### Claim 14 (depends on 10)

The compound of claim 10, wherein R4 is H and R5 is C1-C6-alkyl.

### Claim 15 (depends on 10)

The compound of claim 10, wherein R4 and R5 together form a heterocyclyl selected from the group consisting of morpholinyl, piperidinyl, piperazinyl, and pyrrolidinyl, wherein the morpholinyl, piperidinyl, piperazinyl, and pyrrolidinyl are optionally substituted by 1 or 2 of C1-C6-alkyl, halo, or hydroxy.

### Claim 16 (depends on 10)

The compound of claim 10, wherein X1 and X2 are N;
R1 is H;
R2 is H;
R3 is H or C1-C4-alkyl; and
R4 and R5 together form a heterocyclyl selected from the group consisting of morpholinyl, piperidinyl, piperazinyl, and pyrrolidinyl, wherein the morpholinyl, piperidinyl, piperazinyl, and pyrrolidinyl are optionally substituted by 1 or 2 of C1-C6-alkyl, halo, or hydroxy.

### Claim 17 (depends on 1)

The compound of claim 1 selected from:
or pharmaceutically acceptable salts thereof.

### Claim 18 (depends on 10)

The compound of claim 10, selected from:
or pharmaceutically acceptable salts thereof.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A method for inhibiting the activity of HDAC1 and/or HDAC2 in a subject, comprising administering a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim at position 21

21-34. (canceled)
